Heidelberg Pharma AG

M&A Activity • Oct 14, 2014

News Details

Ad-hoc | 14 October 2014 11:56

WILEX AG: WILEX subsidiary Heidelberg Pharma extends research collaboration with Roche

WILEX AG / Key word(s): Alliance/Agreement

14.10.2014 11:56

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---

Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz
(German Securities Trading Act)

WILEX subsidiary Heidelberg Pharma extends research collaboration with
Roche

Munich, Germany, 14 October 2014 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE)
today announced that WILEX subsidiary Heidelberg Pharma and Roche extended
the existing 2013 licence agreement to apply the antibody drug conjugate
(ADC) technology for the further development of Roche antibodies. The aim
is to identify and develop novel Antibody Targeted Amanitin Conjugates
(ATACs) based on Heidelberg Pharma's patented technology to couple
α-Amanitin to antibodies.

Under the extended licence agreement, Heidelberg Pharma will receive an
upfront payment and further regular payments for granting access to its
technology and providing research services to Roche, which has the
opportunity to exercise options for licences to develop and market selected
ATACs. Heidelberg Pharma will manufacture these substances for clinical
research and receive undisclosed milestone payments and royalties for each
development candidate selected.

Furthermore, exclusive rights to one additional undisclosed tumour target
will be granted to Roche. For this target Heidelberg Pharma could
potentially receive up to EUR 52 million in upfront and milestone payments
for successful clinical development and regulatory approval plus royalties.

---

Information and Explaination of the Issuer to this News:

About WILEX
WILEX AG is a biopharmaceutical company which has a ready for partnering
portfolio of antibody-based diagnostic and therapeutic Phase III product
candidates for the detection and targeted treatment of clear cell renal
cell carcinoma. Research and development now focus on the operations of its
subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances
the development of the innovative platform technology for antibody drug
conjugates (ADC technology) and offers preclinical services. WILEX is
listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / Symbol WL6.
More information is available at www.wilex.com.

Contact IR/PR support
WILEX AG MC Services AG
Corporate Communications Katja Arnold (CIRO)
Sylvia Wimmer Executive Director
Tel.: +49 (0)89-41 31 38-29 Tel.: +49-89-210 228-40
Email: investors[at]wilex.com E-Mail: katja.arnold[at]mc-services.eu
Grillparzerstr. 10, 81675 Munich

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will', 'should', 'future', 'potential' or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

14.10.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE000A11QVV0
WKN: A11QVV
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of Announcement DGAP News-Service

---